Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
$3.2M 22.1%
Total revenue, Q2 '26 (USD).

Did Voyager Therapeutics Beat Earnings?

Voyager Therapeutics (VYGR) reported Q2 '26 revenue of $3.2M, down 39.1% year-over-year.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Voyager Therapeutics’s job postings, web traffic, and employee business outlook. See the full VYGR stock analysis or the earnings calendar for upcoming reports.

Voyager Therapeutics Quarterly Financial Trends (USD)

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue25M6.3M6.5M5.2M13M15M2.6M3.2M
Gross margin-22.8%-422.6%-387.0%-502.5%-168.4%-118.8%64.1%100.0%
Operating margin-56.0%-610.1%-536.0%-704.3%-228.9%-195.2%-1,167.4%-833.9%
Net income-9M-34M-31M-33M-28M-27M-28M-24M
Net margin-36.7%-549.3%-479.2%-642.0%-208.7%-178.8%-1,077.4%-773.2%
EPS————————

Voyager Therapeutics Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Voyager Therapeutics’s quarterly revenue moved from $25M to $3.2M. Net margin compressed from -36.7% to -773.2%, against a 100% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit.

When Is Voyager Therapeutics’s Next Earnings Date?

Voyager Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the VYGR earnings calendar.

Frequently Asked Questions: Voyager Therapeutics Earnings

Voyager Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Voyager Therapeutics reported Q2 '26 revenue of $3.2M, down 39.1% from the same quarter a year earlier.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the VYGR AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.